Vanguard Capital Management
CRNX icon

Vanguard Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vanguard Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178M Buy
4,745,262
+71,327
+2% +$2.65M ﹤0.01% 1216
2026
Q1 		$170M Buy
+4,673,935
New +$209M ﹤0.01% 1160

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's CRNX Position: Q2 2026 in Review

Vanguard Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 1.5% in Q2 2026, buying an estimated $2.65M and bringing the position to 4,745,262 shares worth $178M. The position accounts for ﹤0.01% of the portfolio, ranked #1216.

Vanguard Capital Management first reported a position in CRNX in Q1 2026 and has held it in 2 quarters since. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Vanguard Capital Management held 4,745,262 shares of Crinetics Pharmaceuticals worth $178M as of Q2 2026.
  • Vanguard Capital Management bought 71,327 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.65M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1216 holding.
  • Vanguard Capital Management first reported a position in Crinetics Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.